COVID-19’s outbreak has coincided with investments flooding into nanomedicine healthcare companies, according to the latest data
The World Nano Foundation and Nano Magazine have highlighted a report by marketdataforecast.com that the global nanomedicine market worth $141.34 billion in 2020, will rise to $258.11 billion by 2025.
The report also highlighted a huge upsurge of investment support from governments and funds to develop nano therapies for vaccines, diagnostic imaging, regenerative medicine and drug delivery, following the impact of COVID-19.
Furthermore, nanomedicines offer huge advantages for wider healthcare also impacted by the pandemic and long-COVID after-effects upon cardiovascular, respiratory, neurological and immunological-related diseases.
This aligns with investment -monitoring platform Pitchbook’s forecast that health tech investment overall will top $10 trillion by 2022 and that nanomedicine investment has grown the sector by 250 per cent in the last five years.
Median nanotech healthcare companies deal sizes have also doubled since 2019, from £1 million to £2m in the last 12 months, while the number of deals in 2020 was greater than ever, overtaking 100 deals in a single year for the first time.
Investment is already aiding innovation as nanotech researchers and scientists work to improve biomedical devices such as prosthetics, provide new cancer treatments and develop bone-healing therapies, along with more innovations that could transform global healthcare.
Nanotech researchers have found nanobodies that block COVID-19, and, potentially, other coronaviruses from entering cells and developed mask designs at nanoscale making them both cheaper and more effective.
The fast global response to the pandemic was also enabled by nanotechnology, being pivotal in Pfizer and AstraZeneca vaccine development and Innova Medical Group’s 30-minute lateral-flow COVID tests.
Speaking in this regard, Paul Stannard, Co-founder, World Nano Foundation, said, “COVID-19 highlighted weaknesses in healthcare systems across the developed world, proving that long-term, innovative solutions are needed to enable change and prevent future pandemics, with nanomedicine playing an ever-greater role in this transformation of global healthcare.”
While impressed by rising investments in, and recognition for the nanotech sector, he also warned against any let-up in this trend by saying, “Nanotechnology is not only crucial to our current healthcare systems, but researchers and scientists in this field are on the cusp of therapies, devices and innovation that will revolutionise how we move forward. To ensure pandemic preparedness, high-quality healthcare and longevity, we must invest in nano healthtech and care innovations.”
His message was echoed by Kojo Annan, General Partner, Luxembourg-based Vector Innovation Fund, which recently launched a sub-fund raising an initial $300m for pandemic protection and preparedness.
He said, “Lately, we have seen the development of multiple vaccines, acceleration of technologies linked to decoding the genome, the rise of nanomedicine and the use of artificial intelligence to monitor infectious diseases and new pathogens. More investment in sustainable healthtech funding can only accelerate this trend, bringing fairer and global distribution of healthcare, greater affordability, and preventive and early intervention healthcare, all ultimately improving the longevity of life.”